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Abstract
This case report describes the first reported overdose of the dihydropyridine calcium channel blocker (CCB)
lercanidipine. A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of
lercanidipine. In the department he had a witnessed seizure within 15 minutes of arrival attributed to the
overdose. Following immediate recovery of consciousness after the seizure, he had refractory hypotension and
bradycardia which failed to respond to fluid resuscitation, glucagon therapy, and intravenous calcium. He went on
to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was
successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of
lercanidipine, and the total stay on intensive care was one day before transfer to a ward.
Calcium channel blocker overdose is an uncommon but life-threatening overdose. Treatment for severe toxicity is
similar to b-blocker overdose. Hypotension is treated with intravenous fluid therapy, intravenous calcium and
possibly glucagon with vasopressor or inotropic support as required. Atropine is used to attempt reversal of
bradycardia. High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic
euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit
and potentially superior to fluid therapy, calcium, glucagon and potentially vasopressor therapy. HIET effectively
and sustainably reverses hypotension, bradycardia and improves myocardial contractility and metabolism. Current
advice in calcium channel blocker overdose is to begin therapy early in toxicity, starting with a 1.0 IU/kg insulin
bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.
Background
This is to the authors’ k n o w l e d g et h ef i r s tr e p o r to fa n
overdose on the dihydropyridine calcium channel
blocker lercanidipine. A pubmed search conducted on
July 2010 using the words “lercanidipine,”“ overdose,”
and “poisoning” revealed no results. There are no
known reported cases on Toxbase [1].
Calcium channel blocker (CCB) overdose is an
uncommon overdose, that can cause severe systemic
toxicity. Calcium channel blockers are either dihydro-
pyridine or non-dihydropyridine blockers. Dihydropyri-
dine blocker overdose results in arterial vasodilation and
a reflex tachycardia, but in high enough doses, the per-
ipheral selectivity is lost and it can also affect the
myocardium causing arrhythmias, bradycardia and nega-
tive inotropy [2].
Lercanidipine differs to the other dihydropyridine cal-
cium channel blockers in that it has a half life of
10.5 hrs [3], a long time to peak effect compared to
other calcium channel blockers when exposed directly
to arterial tissue [4] (nifedipine 8.8 mins, verapamil
5.8 mins, lercanidipine 57-63 mins, and amlodipine
106.7 mins) and its effect on the vasomotor reactivity of
smooth muscle is slowest to recover following exposure
and washout [4] (Percent of response when compared
to a standard baseline stimulus applied 95 mins follow-
ing drug wash out; nifedipine 102.2%, verapamil 84.3%,
amlodipine 78.9% and lercanidipine 23.5-47.5%). Com-
pared to the other calcium channel blockers, it is con-
siderably more potent in its action. In rat mesenteric
artery samples the concentration to produce a 50% max-
imal response for S lercanidipine is 22x, 73x and 340x
* Correspondence: georgehadjipavlou@gmail.com
John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
Hadjipavlou et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2011, 19:8
http://www.sjtrem.com/content/19/1/8
© 2011 Hadjipavlou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.less than amlodipine, nifedipine and verapamil respec-
tively [3]; with R lercanidipine being between nifedipine
and verapamil. This means that compared to other cal-
cium channel blockers an overdose on this drug would
take longer to reach maximal effect and longer still for
its toxic effects to wear off.
When assessing a calcium channel blocker overdose,
the time of ingestion, the amount ingested, the release
preparation and the type of blocker are important. Basic
clinical variables obtained during a standard Airway,
Breathing, Circulation and Disability assessment proto-
col may reveal tachypnoea, brady/tachycardia, hypoten-
sion, signs of cardiac failure or changes in conscious
state. An electrocardiogram is needed to identify PR
prolongation and any bradyarrhythmias. A glucose mea-
surement may reveal hyperglycaemia [2]. Laboratory
tests investigating renal function, electrolytes, liver func-
tion, and full blood count should be requested in addi-
tion to a screen for concomitant overdose.
Treatment requires the use of intravenous fluids, glu-
cagon and or calcium infusions, vasopressor therapy.
Treatment with high dose insulinaemic euglycaemia
therapy (HIET) has also been reported. Reports of the
success of calcium and glucagon in reversing toxic side
effects have been documented in case reports and case
series of overdoses on verapamil, diltiazem and nifedi-
pine [5-7]. Success with HIET has been documented
more recently [8]. In the case of lercandipine overdose
described below, a number of therapies were tried to
achieve cardiovascular stability. Success was only
achieved with HIET. We discuss therefore the impor-
tance of this therapy and its possible benefits over other
treatments with this described case adding to the body
of evidence supporting its use.
Case Presentation
A 49 year old male with a previous history of hyperten-
sion was brought into the Emergency Department by
ambulance. He was found asleep with a suicide note and
an empty box of tablets five hours after having been last
seen. On arrival, his observations were: Glasgow Coma
Score 15, respiratory rate 18, heart rate 78 bpm and
blood pressure 98/64 mmHg. Fifteen minutes after arri-
val he suffered a 30 second tonic-clonic seizure with
spontaneous recovery of consciousness. Subsequent
assessment revealed a bradycardia of 50-60 bpm, and a
blood pressure of 77/40 mmHg with maximal head
down tilt.
An initial blood gas revealed a normal pH, sodium,
potassium, calcium, lactate and a glucose level of
6.9 mmol.l
-1. A brief history revealed that this gentleman
had ground up and then ingested 28 tablets of 20 mg ler-
canidipine slow release used to treat his hypertension,
potentially up to 3 hours prior to presentation. The
overdose time was approximately deduced from evi-
dence of activities at the scene. Non-significant doses of
zopiclone (max 15 mg), diazepam (max 20 mg) and
eprosartan (max 1.2 g) were also ingested. It was unclear
exactly how much of the co-ingestants were taken due
to limited information of the tablet size at the time. The
maximum possible dose was determined from knowing
the patient had taken up to 2 tablets of each co-
ingestant and by using the British National Formulary
for the maximum tablet dose availability. No gastroin-
testinal decontamination was performed as is our stan-
dard practice for overdoses presenting more than one
hour after ingestion.
Despite 2 litres of 0.9% sodium chloride given over
5-10 minutes, his systolic blood pressure remained
below 80 mmHg with severe diastolic hypotension of
23 mmHg with maximum head down bed tilt. He was
transferred immediately to the resuscitation room where
he then received 10 mls of 10% calcium chloride
through a large bore peripheral cannula over 15 min-
utes, and 10 mg of glucagon given over 10 minutes
according to advice from Toxbase. Serial ECGs did not
demonstrate any cardiac conduction defects. The PR
interval was normal and the heart rate 50 to 60 bpm.
He remained hypotensive following glucagon and cal-
cium. At this point post seizure, the National Poisons
Information Service was consulted and advised further
boluses of calcium with regular monitoring of serum
calcium levels. High dose insulin therapy at 0.5 IU/kg/hr
was also recommended (hyperinsulinaemic euglycaemia)
if toxicity was severe. He was started immediately on a
noradrenaline infusion targeting a mean arterial pressure
of more than 70 mmHg and following this high dose
insulin HIET (60 IU/hour; 0.5 IU/kg/hour where
weight = 120 kg) in the resuscitation room without
a bolus dose. A glucose infusion was started at 100
mls/hour of 20% dextrose. He was subsequently trans-
ferred to intensive care. No further boluses of calcium
nor glucagon were given due to the initial rapid
response to HIET. The initial noradrenaline dose was
0.235 microg/kg/min; noradrenaline was required for a
total of 9-10 hours during which time it was gradually
weaned. Hyperinsulinaemic euglycaemia therapy was
continued for 8 hours after. Figure 1 illustrates the
treatments tried over the course of the admission
plotted with haemodynamic parameters. Blood glucose
levels ranged from 5.6-14.7 mmol/l, and a total of 60
mmol/l of potassium was given. Insulin therapy was gra-
dually weaned and his blood pressure remained stable.
He was transferred to the medical ward the following
day and discharged home two days after admission fol-
lowing psychiatric assessment.
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Treatment for this specific case required a number of
the therapies described for significant CCB overdose.
However cardiovascular stability was only achieved fol-
lowing institution of hyperinsulinaemic euglycaemia
therapy (HIET). A review of the literature reveals that
HIET is potentially superior to other treatment options
for calcium channel blocker overdose. An in depth
review has been made by Lheureux et al [9] and the
authors direct the reader to this review for more infor-
mation. A brief review of the human and animal litera-
ture is provided here.
This case study demonstrates the rapid haemodynamic
stabilization achieved with HIET. This has been seen in
both animal models of calcium channel blocker overdose
and in a limited number of human case studies. Kline et al,
[10] demonstrated using a canine model of intravenous
verapamil overdose, that HIET therapy was superior to
intravenous fluids, epinephrine therapy, and glucagon ther-
apy. Twenty-four anaesthetised dogs received verapamil at
0.1 mg/kg/min until a 50% reduction in blood pressure or
AV dissociation for greater than 30 minutes was achieved.
Four groups of six dogs received either fluid therapy, gluca-
gon, epinephrine or HIET. Outcome was mortality at
240 mins. All those receiving fluid therapy died within
85 minutes. 50% of the glucagon group, and 66% of the
epinephrine group had died at 240 mins. There were no
deaths in the HIET group. Kline et al, [11] later demon-
strated in a canine model that verapamil toxicity renders
the heart dependent on carbohydrate metabolism, and
HIET was superior to glucagon, adrenaline and calcium
chloride in producing the largest increases in the myocar-
dial use of lactate following verapamil toxicity. This was
associated with a better outcome compared to the other
therapies.
There are few case studies documenting the efficacy
and safety of HIET in human CCB overdose. Yuan et al,
[8] describes four cases of verapamil overdose, all suffer-
ing with hypotension, bradycardia and acidosis that was
reversed with HIET when a combination of calcium, glu-
cagon and epinephrine therapy had failed to maintain
cardiovascular stability. HIET restored and maintained a
significant rise in both systolic and diastolic blood pres-
sure. In one case, an echocardiogram demonstrated an
improvement in ejection fraction from 10 to 50% 3 hrs
following institution of HIET. This particular case study
presented with hypotension, bradycardia and a seizure.
Like the case studies, both calcium and glucagon were
administered, but these therapies were not continued.
Instead HIET was instituted immediately and with
observable therapeutic effect. Haemodynamic stability
was achieved within 1 hour of the onset of treatment
(Figure 1). In other case studies [8], response to HIET has
been variable (20 mins to 2 hrs). Though noradrenaline
Figure 1 Time course of heart rate and blood pressure with response to therapies. Infusions are plotted as curves with rates on the y-axis.
Single bolus therapies are named only; doses can be found in the text in the case description.
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initiation of HIET) whilst haemodynamic stability was
maintained on HIET.
The authors believe that stability was achieved by
HIET and not noradrenaline. Withdrawal of noradrena-
line was started four hours after HIET initiation; which
is not enough time for the serum level of lercanidipine
to drop significantly. Assuming a half life of 10.5 hrs [3],
there would been more than 50% of the drug remaining
compared to when HIET was started; and 40% of the
total overdose remaining when noradrenaline was
stopped. Unfortunately serum drug levels are not avail-
able, and the human toxic range of lercanidipine is
unknown. A pubmed search using the items “lercanidi-
pine, LD50, toxicity, lethal” revealed no valuable results.
The lethal dose 50% for oral lercanidipine occurs in
male rats, mice and dogs at 939 mg.kg
-1, 622 mg.kg
-1
and >300 mg.kg
-1 [ 1 2 ] .T h es i n g l et o x i cd o s et h e r e f o r e
in this case works out as 4.67 mg.kg
-1 (weight = 120 kg
and dose 560 mg). This is considerably different to the
animal literature.
Based on a review of current available cases, and experi-
mental data, Lheureux et al, [9] recommends treatment
with HIET in CCB overdose with administration of a
1.0 IU/kg IV insulin bolus followed by an infusion of
0.5 IU/kg/hr insulin. This should be co-administered with
a high concentration of glucose (some adult requirements
range from 20-30 g/h) with half hourly checks of glucose
levels. Therapy should be guided by clinical response and
haemodynamic stability with the aim to achieve withdra-
wal of vasoactive agents whilst maintaining cardiovascular
stability. Treatment should be started early, as there is a
small body of evidence to suggest that benefits of HIET
are lost if initiation is late [9]. Cumpston K et al describe 3
cases where HIET failed in diltiazem overdose [13]. In one
case HIET was initiated 5.5 hrs post ingestion of 32 g of
diltiazem (though this is an extreme overdose). The
patient did not survive. The remaining two cases describe
failure of HIET to achieve haemodynamic stability when
initiated at 13 hrs and 9.5 hrs post ingestion of 7.2 g and
3.4 g of diltiazem; with one case dying and the other
remaining in a persistent vegetative state. In the successful
case series described by Yuan TH et al [8], the time to
initiation of HIET was 3-7 hrs in those cases where it
could be ascertained from the information provided. It is
understandably hard to make a fair comparison from the
lack of numbers and the range of drugs and doses over-
dosed on. For the above described case, HIET was initiated
within 7 hrs of suspected overdose time.
Conclusions
This is the first reported case of overdose on the dihy-
dropyridine calcium channel blocker lercanidipine.
Management in this case report agrees with animal
literature and the limited studies available that HIET is
potentially superior to other treatments for CCB over-
dose and its early administration is most likely to be
beneficial.
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